Mylotarg (gemtuzumab ozogamicin) has been approved for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).
AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.
Mylotarg is a targeted therapy that consists of an antibody connected to an anti-tumor agent that is toxic to cells. It is thought to work by taking the anti-tumor agent to the AML cells that express the CD33 antigen, blocking the growth of cancerous cells and causing cell death.
Common side effects of Mylotarg are fever, nausea, infection, vomiting, bleeding, low levels of platelets in the blood, swelling and sores in the mouth, constipation, rash, headache, liver damage, and low levels of certain white blood cells.
haleplushearty.blogspot.com
No comments:
Post a Comment